MedTrace Logo

OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol

NCT03881904 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 740

Last updated 2019-03-20

No results posted yet for this study

Summary

373 women with PCOS undergoing a trial of IVF/ICSI will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Another 373 women with PCOS undergoing a trial of IVF/ICSI will start GnRH antagonist COH directly without OCP pretreatment.

Both groups will be followed up for effect on ongoing pregnancy rate.

Conditions

  • Subfertility, Female

Interventions

DRUG

0.075mg gestodene/0.03mg ethinylestradiol

OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Mostafa Fouad, MD · Assistant Professor

  • Ahmed Abbas, MD · Lecturer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-07-01
Completion
2019-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881904 on ClinicalTrials.gov